Capstone Investment Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Capstone Investment Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$284K	Sell	11,480 -2,762	-19%	-$65.8K	﹤0.01%	1385
2025 Q4	$332K	Buy	+14,242	New	+$317K	﹤0.01%	1301
2025 Q1	–	Sell	-16,173	Closed	-$338K	–	1446
2024 Q4	$338K	Sell	16,173 -19,434	-55%	-$418K	﹤0.01%	1447
2024 Q3	$708K	Buy	+35,607	New	+$660K	﹤0.01%	1095
2024 Q2	–	Sell	-22,616	Closed	-$360K	–	2149
2024 Q1	$360K	Buy	+22,616	New	+$341K	﹤0.01%	1730

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capstone Investment Advisors's CPRX Position: Q1 2026 in Review

Capstone Investment Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 19% in Q1 2026, selling an estimated $65.8K and leaving 11,480 shares worth $284K. The position accounts for ﹤0.01% of the portfolio, ranked #1385.

Capstone Investment Advisors first reported a position in CPRX in Q1 2024 and has held it in 5 quarters since. The position peaked at $708K in Q3 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Capstone Investment Advisors held 11,480 shares of Catalyst Pharmaceutical worth $284K as of Q1 2026.
Capstone Investment Advisors sold 2,762 Catalyst Pharmaceutical shares in Q1 2026, an estimated $65.8K.
Catalyst Pharmaceutical made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #1385 holding.
Capstone Investment Advisors first reported a position in Catalyst Pharmaceutical in Q1 2024 and has held it in 5 quarters since.
Capstone Investment Advisors's Catalyst Pharmaceutical position peaked at $708K in Q3 2024.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.